Maxim Group Downgrades Mast Therapeutics (MSTX) to Hold Following Vepoloxamer Phase 3 Miss
- Wall St stocks end higher with major corporate earnings in view
- SAP Q1 results fall short of Wall Street estimates as transformation kicks off
- Cadence (CDNS) tumbles despite Q1 beat on top and bottom lines
- Tesla expands price cuts to China, Germany after reducing FSD cost; shares down
- Gold prices slide as M.East fears ease, rate jitters persist
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Kroger (KR), Albertsons and C&S Wholesale Grocers Announce an Updated and Expanded Divestiture Plan
- Costar Group (CSGP) to Acquire Matterport (MTTR) for $5.50/sh Cash and Stock
- Jaguar Health (JAGX) Files $75M Mixed Shelf
- Apple (AAPL) PT Lowered to $210 at Morgan Stanley, 'We'd buy post-earnings weakness'
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
Laidlaw Downgrades Mast Therapeutics (MSTX) to Neutral
September 21, 2016 11:46 AM EDTLaidlaw downgraded Mast Therapeutics (NYSE: MSTX) from Buy to Neutral.
For an analyst ratings summary and ratings history on Mast Therapeutics click here. For more ratings news on Mast Therapeutics click here.
Shares of Mast Therapeutics closed at $0.59 yesterday.
... MoreMast Therapeutics (MSTX) Reports Vepoloxamer Phase 3 in Sickle Cell Missed Primary Endpoint
September 20, 2016 5:02 PM EDTMast Therapeutics, Inc. (NYSE: MSTX) reported top-line results from EPIC, a Phase 3 clinical study of its investigational new drug vepoloxamer (also known as MST-188) for the treatment of individuals with sickle cell disease experiencing vaso-occlusive crisis (VOC). The study did not meet its primary efficacy endpoint of demonstrating a statistically significant reduction in the mean duration of VOC (82 hours in the vepoloxamer group compared to 78 hours in the placebo group in the intent-to-treat population (p=0.09)). There were no statistically significant differences... More